+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Abcam Ltd - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 41 Pages
  • July 2024
  • GlobalData
  • ID: 5988455
Abcam Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Abcam Ltd (Abcam) a subsidiary of Danaher Corp, is a supplier of life science research tools for analysis of living cells at the molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondary antibodies, immunoassay kits and reagents, cell and tissue imaging tools, cellular and biochemical assays, proteomics tools, proteins and peptides, activators, agonists, antagonists and inhibitors, lysates, and multiplex miRNA assay. Abcam’s products serve life science researchers to identify proteins for life sciences and veterinary sciences. The company distributes its products in the Americas, Europe, Asia-Pacific, and other countries. Abcam is headquartered in Cambridge, Cambridgeshire, the UK.

Abcam Ltd Key Recent Developments

  • Apr 22, 2024: Recently Completed Project: Abcam - Phase II & III
  • Mar 18, 2024: Abcam Appoints Markus Lusser as New President
  • Jun 16, 2023: Abcam plc files and mails Shareholder Circular calling an Extraordinary General Meeting
  • May 30, 2023: Abcam announces statement on calling an extraordinary general meeting

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Abcam Ltd - Key Facts
  • Abcam Ltd - Key Employees
  • Abcam Ltd - Major Products and Services
  • Abcam Ltd - History
  • Abcam Ltd - Company Statement
  • Abcam Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Abcam Ltd - Business Description
  • R&D Overview
  • Abcam Ltd - Corporate Strategy
  • Abcam Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Abcam Ltd - Strengths
  • Abcam Ltd - Weaknesses
  • Abcam Ltd - Opportunities
  • Abcam Ltd - Threats
  • Abcam Ltd - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Abcam Ltd, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • Abcam Ltd, Medical Equipment, Deals By Type, 2018 to YTD 2024
  • Abcam Ltd, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Apr 22, 2024: Recently Completed Project: Abcam - Phase II & III
  • Mar 18, 2024: Abcam Appoints Markus Lusser as New President
  • Jun 16, 2023: Abcam plc files and mails Shareholder Circular calling an Extraordinary General Meeting
  • May 30, 2023: Abcam announces statement on calling an extraordinary general meeting
  • May 17, 2023: ABCAM Result of Annual General Meeting
  • May 17, 2023: Abcam: Statement on potential extraordinary general meeting
  • Mar 30, 2023: Abcam Publication of 2022 Annual Report and Accounts and Notice of Annual General Meeting
  • Mar 30, 2023: Abcam Publication of 2022 Annual Report and Accounts and Notice of Annual General Meeting
  • Mar 10, 2023: Abcam to Report Full Year Results on Monday, March 20, 2023
  • Jan 30, 2023: ABCAM : Trading update
Section 5 - Appendix
  • Methodology
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Abcam Ltd, Key Facts
  • Abcam Ltd, Key Employees
  • Abcam Ltd, Major Products and Services
  • Abcam Ltd, History
  • Abcam Ltd, Subsidiaries
  • Abcam Ltd, Key Competitors
  • Abcam Ltd, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • Abcam Ltd, Medical Equipment, Deals By Type, 2018 to YTD 2024
  • Abcam Ltd, Recent Deals Summary
List of Figures
  • Abcam Ltd, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • Abcam Ltd, Medical Equipment, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Siemens Healthineers AG
  • Illumina Inc
  • F. Hoffmann-La Roche Ltd
  • bioMerieux SA
  • Beckman Coulter Inc